Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | TNKS | O95271 | 1/20 | 0.62 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107542 | 1.00 | PTGS2 (0.63) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| Benzophenone SCHEMBL7199379 | 0.89 | HCAR2 (0.79) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| Benzophenone SCHEMBL7199376 | 0.89 | HCAR2 (0.79) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL69236 | 0.85 | P4HB (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL69237 | 0.85 | P4HB (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11124806 | 0.84 | MAOB (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11124804 | 0.84 | MAOB (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10386290 | 0.83 | SRD5A2 (0.75) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3651653 | 0.83 | SRD5A2 (0.75) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL271386 | 0.82 | NPSR1 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2020-12-10 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2017-12-21 | — | — | US | disclosed |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | disclosed |
| EP-2659885-B1 | Hepatitis C Antiviral Compositions and Methods | BIOTRON LTD (AU) | 2016-11-09 | — | — | EP | disclosed |
| US-9440926-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2016-09-13 | — | — | US | disclosed |
| EP-2194976-B1 | Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine | BIOTRON LTD (AU) | 2015-12-09 | — | — | EP | disclosed |
| US-20150023921-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| EP-2826770-A1 | Acylguanidine compounds with antiviral activity | Biotron Limited (AU) | 2015-01-21 | — | — | EP | disclosed |
| US-8669280-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2014-03-11 | — | — | US | disclosed |
| US-20140066487-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2014-03-06 | — | — | US | disclosed |
| EP-2659885-A1 | Hepatitis C Antiviral Compositions and Methods | Biotron Limited (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | disclosed |
| EP-2194976-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | Biotron Limited (AU) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008060844-A1 | POLYMERIZATION INHIBITOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE | ALBEMARLE CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066487-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 2704/4885HDAC3 681/4885HDAC4 469/4885 |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PTGS2 1322/4885HDAC3 690/4885HDAC4 1456/4885 |
| US-20150023921-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PTGS2 1322/4885HDAC3 690/4885HDAC4 1456/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 2704/4885HDAC3 681/4885HDAC4 469/4885 |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PTGS2 1322/4885HDAC3 690/4885HDAC4 1456/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 2704/4885HDAC3 681/4885HDAC4 469/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 2704/4885HDAC3 681/4885HDAC4 469/4885 |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | PTGS2 1322/4885HDAC3 690/4885HDAC4 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.